Advances in understanding of toxicities of treatment for head and neck cancer
- PMID: 19467918
- DOI: 10.1016/j.oraloncology.2009.03.018
Advances in understanding of toxicities of treatment for head and neck cancer
Abstract
Toxicities associated with head and neck cancer treatment are common events. Despite the fact that many side effects of cancer treatment are now well controlled, some, such as mucositis and salivary gland hypofunction, continue to be almost inevitable outcomes of cancer treatment. Furthermore, improvements in cancer treatment itself as well as new modalities, such as targeted treatments, may be associated with different toxicities. In this review, common toxicities associated with head and neck cancer treatment will be discussed including those reported to occur with targeted therapies. This review also considers the concept of toxicity clusters, risk factors for toxicity (for example genetics) and individualisation of cancer treatment.
Similar articles
-
Treatment of head and neck cancers: issues for clinical pharmacists.Pharmacotherapy. 2009 May;29(5):578-92. doi: 10.1592/phco.29.5.578. Pharmacotherapy. 2009. PMID: 19397465 Review.
-
Salivary gland sparing in the treatment of head and neck cancer.Expert Rev Anticancer Ther. 2011 Sep;11(9):1437-48. doi: 10.1586/era.11.101. Expert Rev Anticancer Ther. 2011. PMID: 21929317 Review.
-
A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1079-83. doi: 10.1016/j.ijrobp.2008.12.053. Epub 2009 Mar 26. Int J Radiat Oncol Biol Phys. 2009. PMID: 19327910 Clinical Trial.
-
Management of the oral sequelae of cancer therapy.Tex Dent J. 2012 May;129(5):461-8. Tex Dent J. 2012. PMID: 22779202
-
Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.Semin Oncol. 2004 Dec;31(6 Suppl 18):8-12. doi: 10.1053/j.seminoncol.2004.12.005. Semin Oncol. 2004. PMID: 15726516 Clinical Trial.
Cited by
-
Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.Oncotarget. 2015 Apr 20;6(11):9045-60. doi: 10.18632/oncotarget.3515. Oncotarget. 2015. PMID: 25826087 Free PMC article.
-
Burden, quality of life, and social support in caregivers of patients undergoing radiotherapy for head and neck cancer: A pilot study.Chronic Illn. 2016 Sep;12(3):236-45. doi: 10.1177/1742395316644305. Epub 2016 Apr 10. Chronic Illn. 2016. PMID: 27068111 Free PMC article.
-
Genome stability pathways in head and neck cancers.Int J Genomics. 2013;2013:464720. doi: 10.1155/2013/464720. Epub 2013 Nov 4. Int J Genomics. 2013. PMID: 24364026 Free PMC article. Review.
-
Oncologic outcomes and patient-reported quality of life in patients with oropharyngeal squamous cell carcinoma treated with definitive transoral robotic surgery versus definitive chemoradiation.Oral Oncol. 2016 Oct;61:41-6. doi: 10.1016/j.oraloncology.2016.08.004. Epub 2016 Aug 25. Oral Oncol. 2016. PMID: 27688103 Free PMC article.
-
Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo.Otolaryngol Head Neck Surg. 2012 Jun;146(6):938-45. doi: 10.1177/0194599812436648. Epub 2012 Feb 8. Otolaryngol Head Neck Surg. 2012. PMID: 22323435 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical